Wu, Zenan
Hu, Zehao
Ke, Shiwen
Mo, Lisha
Qiu, Mingliang
Zhu, Guoshuang
Zhu, Wei
Liu, Liangji
Funding for this research was provided by:
Natural Science Foundation of Jiangxi Province (No.20212BAB216061, No.20212BAG70038, No.2019ACBL20023)
jiangxi Clinical Medical Research Center of Lung Diseases (Gan ke fa she [2019] No. 44)
Jiangxi Provincial Key Laboratory of Traditional Chinese Medicine Epidemic Diseases (Jiangxi Traditional Chinese Medicine Science and Education Zi [2021] No. 3)
Clinical Study on the Treatment of COVID-19 with Traditional Chinese Medicine (No.2020YBBGW0003)
Jiangxi University of Chinese Medicine Science and Technology Innovation Team Development Program (No.CXTD22011)
Article History
Received: 9 March 2023
Accepted: 25 April 2023
First Online: 12 May 2023
Declarations
:
: The study protocol complied with the ethical standards described in the Declaration of Helsinki. All methods of this study were performed in accordance with the relevant guidelines and regulations. The procedures implemented in this study adhered to the International Guidelines for Human Biomedical Research Ethics and the Declaration of Helsinki. The Ethics Committee of the First Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine granted approval for the study (approval number: JZFYLL202202230011). Furthermore, the study was registered with the Chinese Clinical Trials Registry (registration number: ChiCTR2200055559, registered on January 12, 2022). Any alterations or modifications to the study protocol must be communicated to the Ethics Committee of the First Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, China, and reported to the Chinese Clinical Trials Registry. All patients provided written informed consent and were aware of the potential benefits and risks.
: Informed consent for publication was obtained from every participant.
: The authors declare that they have no competing interests